Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV

Inclusion Criteria: * Serologically-confirmed HIV and HBV infection * Gestational age less than 28 weeks * Willingness to participate in a clinical trial * Age 20 years or over on the day of inclusion * Willingness to return for follow-up visits and to allow infant participation in the trial * Intent to remain in the clinic catchment area during the duration of the study * No serious current complications of pregnancy * No previous or current use of antiretrovirals including the HIVNET 012 regiment * Hemoglobin over 8 g/dL * Blood creatinine clearance greater than or equal to 60 mL/min estimated by the Cockroft-Gault formula for women Exclusion Criteria: * Age less than 20 * Pregnant woman refuses to sign the consent to participate * Unwillingness to adhere to visit schedule or maintain adherence with medications * Illnesses so severe as to likely require maternal hospitalization * Intend to breastfeed